INT93532

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2001
Last Reported 2010
Negated 1
Speculated 2
Reported most in Body
Documents 14
Total Number 16
Disease Relevance 10.75
Pain Relevance 2.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Tnfsf11) extracellular space (Tnfsf11) extracellular region (Tnfsf11)
plasma membrane (Tnfsf11) intracellular (Tnfsf11) cytoplasm (Tnfsf11)
Anatomy Link Frequency
osteoclast 6
stromal cell 1
Tnfsf11 (Mus musculus)
Pain Link Frequency Relevance Heat
cINOD 4 99.76 Very High Very High Very High
Spinal cord 3 98.12 Very High Very High Very High
agonist 44 97.12 Very High Very High Very High
Pain 11 96.84 Very High Very High Very High
cytokine 117 96.44 Very High Very High Very High
Arthritis 237 92.12 High High
Inflammation 204 86.44 High High
Inflammatory response 11 80.88 Quite High
rheumatoid arthritis 194 66.96 Quite High
Inflammatory marker 2 65.68 Quite High
Disease Link Frequency Relevance Heat
Hypercalcemia 101 99.84 Very High Very High Very High
Cancer 69 99.68 Very High Very High Very High
Bone Cancer 33 99.04 Very High Very High Very High
Osteoporosis 75 98.84 Very High Very High Very High
Spinal Cord Compression 3 98.60 Very High Very High Very High
INFLAMMATION 162 98.32 Very High Very High Very High
Pain 8 96.84 Very High Very High Very High
Necrosis 19 96.20 Very High Very High Very High
Malignant Neoplastic Disease 8 95.64 Very High Very High Very High
Osteolysis 8 94.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The latter finding is consistent with the notion that RANKL levels are modulated by stromal cell-expressed VCAM-1 binding to very late antigen-4 on myeloma tumor cells [5].
Regulation (modulated) of RANKL in stromal cell associated with cancer
1) Confidence 0.42 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924519 Disease Relevance 1.01 Pain Relevance 0.04
in the negative regulation of RANKL- and c-Fos-dependent osteoclast differentiation [14].
Regulation (regulation) of RANKL in osteoclast
2) Confidence 0.27 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC416442 Disease Relevance 0.42 Pain Relevance 0.17
Serum OPG values for patients were not greater than in controls, but showed a statistically significant trend to increase with age (P = 0.057).
Regulation (values) of OPG
3) Confidence 0.23 Published 2006 Journal Br. J. Haematol. Section Abstract Doc Link 16512834 Disease Relevance 0.55 Pain Relevance 0.07
Osteoclast differentiation and activation is controlled, at least in part, by the counterbalancing influences of osteoprotegerin ligand (OPGL) and osteoprotegerin (OPG).
Regulation (influences) of OPG in Osteoclast
4) Confidence 0.22 Published 2001 Journal Bone Section Abstract Doc Link 11182380 Disease Relevance 0.19 Pain Relevance 0.10
Osteoclast differentiation and activation is controlled, at least in part, by the counterbalancing influences of osteoprotegerin ligand (OPGL) and osteoprotegerin (OPG).
Regulation (influences) of osteoprotegerin in Osteoclast
5) Confidence 0.22 Published 2001 Journal Bone Section Abstract Doc Link 11182380 Disease Relevance 0.19 Pain Relevance 0.10
Importantly, genes associated with bone destruction such as RANKL, MMP9, ATPV0D2, and TRAP are down-regulated in paws after MDL-1–Ig fusion treatment and up-regulated in anti–MDL-1 agonist treatment.
Regulation (regulated) of RANKL associated with agonist
6) Confidence 0.19 Published 2010 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2839155 Disease Relevance 0.39 Pain Relevance 0.29
OPG has been identified as a regulator of bone formation and resorption [15].
Regulation (regulator) of OPG
7) Confidence 0.14 Published 2010 Journal J Int AIDS Soc Section Body Doc Link PMC2859852 Disease Relevance 1.79 Pain Relevance 0.11
may not only promote osteoclast generation, but they also appear to stimulate mature osteoclasts to perform more resorption cycles through modulation of RANKL activity.
Regulation (modulation) of RANKL in osteoclast
8) Confidence 0.14 Published 2005 Journal Immun Ageing Section Body Doc Link PMC1308846 Disease Relevance 0.65 Pain Relevance 0.27
-estradiol has been shown to increase OPG mRNA and protein levels in human osteoblastic cell lines [43], whereas other workers did not find that OPG was regulated by estrogen [44].
Regulation (regulated) of OPG associated with osteoporosis
9) Confidence 0.13 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC165058 Disease Relevance 0.19 Pain Relevance 0.07
The apparent regulation of the TRAP, RANKL, ATPV0D2, and MMP9 expression after anti–MDL-1 treatment suggests MDL-1 receptor activation may promote osteoclast development and function.
Regulation (regulation) of RANKL in osteoclast
10) Confidence 0.11 Published 2010 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2839155 Disease Relevance 0.34 Pain Relevance 0.21
Thus, it is worthwhile considering the possibility that inhibition of osteoclast function using other novel strategies that target RANKL [78, 79] may also be required in this context.
Regulation (target) of RANKL in osteoclast
11) Confidence 0.06 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2842969 Disease Relevance 0.61 Pain Relevance 0.34
This paper is an overview of the involvement of the micro-environment, as represented by the balance of RANKL/TRAIL and the presence of proteoglycans in the regulation of OPG biological activity in bone tumors.
Regulation (regulation) of OPG associated with bone cancer
12) Confidence 0.06 Published 2010 Journal Biochim. Biophys. Acta Section Abstract Doc Link 19733222 Disease Relevance 0.98 Pain Relevance 0.06
Both RANKL and OPG can be aberrantly regulated in the cancer setting and function as important gatekeepers of tumor-induced osteolytic bone disease.
Regulation (regulated) of OPG associated with cancer and bone cancer
13) Confidence 0.04 Published 2008 Journal Cancer Treat. Rev. Section Abstract Doc Link 17964729 Disease Relevance 1.48 Pain Relevance 0.14
It remains to be identified whether OPG-L is a good target for the prevention of bone erosion or whether it is safer to target the inducing and modulating cytokines.
Spec (whether) Regulation (target) of OPG-L associated with cytokine
14) Confidence 0.03 Published 2001 Journal Arthritis Res Section Body Doc Link PMC128880 Disease Relevance 0.45 Pain Relevance 0.28
Three proteins, RANKL, RANK, and OPG have been recently identified as key determinants of osteoclastogenesis and the regulation of bone resorption.
Spec (determinants) Regulation (regulation) of OPG associated with hypercalcemia
15) Confidence 0.02 Published 2008 Journal Cancer Treat. Rev. Section Abstract Doc Link 17964729 Disease Relevance 1.46 Pain Relevance 0.15
Serum levels of OPG and RANKL were not changed.
Neg (not) Regulation (changed) of OPG
16) Confidence 0.01 Published 2007 Journal J. Rheumatol. Section Body Doc Link 17610317 Disease Relevance 0.05 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox